Working… Menu
Trial record 1 of 1 for:    ovar 2.21
Previous Study | Return to List | Next Study

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01837251
Recruitment Status : Unknown
Verified December 2018 by AGO Research GmbH.
Recruitment status was:  Active, not recruiting
First Posted : April 23, 2013
Last Update Posted : December 19, 2018
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Australia New Zealand Gynaecological Oncology Group
Scottish Gynaecological Cancer Study Group
Information provided by (Responsible Party):
AGO Research GmbH